GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
GeNeuro, 28 Aug 2014
Accessed on 8 Sep 2014 from http://www.geneuro.com/files/documents/Press_release_Geneuro_28_august_2014.pdf.